DI-074 Evaluation of the treatment response with the new direct acting antiviral drugs for the treatment of hepatitis C virus infection in cirrhotic patients
| Autor: | N Vicente Oliveros, MA Rodríguez Sagrado, T. Bermejo Vicedo, M. Vélez-Díaz-Pallarés, MA Parro Martin, Pintor Recuenco |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
medicine.diagnostic_test business.industry medicine.medical_treatment Hepatitis C virus Retrospective cohort study Disease Liver transplantation medicine.disease_cause Virus Surgery Internal medicine Relative risk medicine Blood test General Pharmacology Toxicology and Pharmaceutics business Direct acting |
| Zdroj: | European Journal of Hospital Pharmacy. 23:A151.1-A151 |
| ISSN: | 2047-9964 2047-9956 |
| Popis: | Background The emergence of new direct acting antiviral drugs (DAAs) for hepatitis C virus (HCV) has been a major advance in the treatment of disease. It is interesting to see the results of the first patients treated in our setting. Purpose To evaluate the effectiveness of treatment with the new DAAs in monoinfected patients with HCV and coinfected with HCV and HIV. Material and methods Retrospective observational study at a university hospital in Spain. All cirrhotic patients who started treatment with DAAs against HCV from September 2014 until February 2015 were included. An investigator registered if the patient was coinfected with HIV and if the patient was liver transplanted. A blood test was done 12 weeks after the beginning of treatment. Sustained virologic response was defined as aviraemia 12 weeks after completion of antiviral treatment (SVR12). SVR12 was the measure of effectiveness. Outcomes for effectiveness were expressed using the percentage of patients with SVR12 divided by the total number of treated patients times 100. Monoinfected and coinfected patient effectiveness was compared by calculating relative risk (RR) ratios with 95% CI. Results 42 patients were treated for 12 weeks. At week 12, 83.3% of patients (n = 35) were negative for the virus but 7 had positive HCV blood tests. Of the 35 patients with negative blood tests, all were still negative 12 weeks after treatment had finished. Therefore, SVR12 was 83.3% (35 out of 42). Of these 42 patients 57.1% (n = 24) had received prior liver transplantation and 66.6% (n = 28) were coinfected with HIV. Of the 7 patients with treatment failure, 57.1% (n = 4) were liver transplanted and 71% (n = 5) were coinfected with HIV. No statistically significant differences in effectiveness were observed between monoinfected and coinfected patients (RR=1.25 (95% CI 0.28 to 5.65)). Conclusion Treatment with new DDAs was effective in cirrhotic patients, with SVR12 rates of approximately 83%. No differences in effectiveness were observed between coinfected and monoinfected patients. No conflict of interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|